BioHarvest In Vitro Testing Shows Proprietary Olive Cell Compound Reduces Fat Accumulation in Liver Cells
BioHarvest Sciences (NASDAQ: BHST) has announced promising in vitro test results for their proprietary Olive Cell compound, showing reduced fat accumulation in human liver cells. The compound, rich in Verbascoside, demonstrated effectiveness in mitigating fat accumulation in liver steatosis and fibrosis models.
The development targets Non-Alcoholic Fatty Liver Disease (NAFLD), which affects 30-40% of U.S. adults, with its severe form NASH impacting 3-5% of the adult population. The company plans to launch the Olive Cell product as a nutraceutical in 2026, while exploring pharmaceutical partnerships.
The tests, conducted on human hepatic cells, showed the compound's ability to reduce collagen type 1 levels in XL-2 cells. This product will join VINIA® in BioHarvest's portfolio, which has already achieved over $50M USD in sales with 50,000+ active subscribers.
BioHarvest Sciences (NASDAQ: BHST) ha annunciato risultati promettenti da test in vitro per il loro composto proprietario Olive Cell, mostrando una riduzione dell'accumulo di grasso nelle cellule epatiche umane. Il composto, ricco di Verbascoside, ha dimostrato efficacia nel mitigare l'accumulo di grasso nei modelli di steatosi epatica e fibrosi.
Lo sviluppo mira a Malattia Fegatale Grassa Non Alcolica (NAFLD), che colpisce il 30-40% degli adulti negli Stati Uniti, con la sua forma severa NASH che impatta il 3-5% della popolazione adulta. L'azienda prevede di lanciare il prodotto Olive Cell come nutraceutico nel 2026, mentre esplora partnership farmaceutiche.
I test, condotti su cellule epatiche umane, hanno mostrato la capacità del composto di ridurre i livelli di collagene di tipo 1 nelle cellule XL-2. Questo prodotto si unirà a VINIA® nel portfolio di BioHarvest, che ha già raggiunto oltre 50 milioni di dollari in vendite con più di 50.000 abbonati attivi.
BioHarvest Sciences (NASDAQ: BHST) ha anunciado resultados prometedores de pruebas in vitro para su compuesto exclusivo Olive Cell, que muestra una reducción en la acumulación de grasa en las células del hígado humano. El compuesto, rico en Verbascósido, demostró ser efectivo para mitigar la acumulación de grasa en modelos de esteatosis hepática y fibrosis.
El desarrollo se centra en la Enfermedad Hepática Grasa No Alcohólica (NAFLD), que afecta al 30-40% de los adultos en EE. UU., siendo su forma severa NASH impactando al 3-5% de la población adulta. La empresa planea lanzar el producto Olive Cell como nutracéutico en 2026, mientras explora asociaciones farmacéuticas.
Las pruebas, realizadas en células hepáticas humanas, mostraron la capacidad del compuesto para reducir los niveles de colágeno tipo 1 en células XL-2. Este producto se unirá a VINIA® en el portafolio de BioHarvest, que ya ha alcanzado más de 50 millones de dólares en ventas con más de 50,000 suscriptores activos.
BioHarvest Sciences (NASDAQ: BHST)는 독점적인 올리브 셀 화합물에 대한 유망한 시험 관찰 결과를 발표했으며, 이는 인간 간세포에서 지방 축적을 줄이는 것으로 나타났습니다. Verbascoside가 풍부한 이 화합물은 간 지방증 및 섬유증 모델에서 지방 축적을 완화하는 데 효과적임을 입증했습니다.
이 개발은 비알콜성 지방간 질환 (NAFLD)를 목표로 하며, 이는 미국 성인의 30-40%에 영향을 미치고, 그 심각한 형태인 NASH는 성인 인구의 3-5%에 영향을 미칩니다. 회사는 2026년에 올리브 셀 제품을 영양소로 출시할 계획이며, 제약 파트너십도 탐색하고 있습니다.
인간 간세포에서 실시된 테스트는 이 화합물이 XL-2 세포에서 콜라겐 타입 1 수준을 줄이는 능력을 보여주었습니다. 이 제품은 BioHarvest의 포트폴리오에 있는 VINIA®와 함께할 것이며, 이미 50,000명 이상의 활성 구독자와 함께 5천만 달러 이상의 매출을 달성했습니다.
BioHarvest Sciences (NASDAQ: BHST) a annoncé des résultats d'essai in vitro prometteurs pour leur composé exclusif Olive Cell, montrant une réduction de l'accumulation de graisse dans les cellules hépatiques humaines. Le composé, riche en Verbascoside, a démontré son efficacité à atténuer l'accumulation de graisse dans les modèles de stéatose hépatique et de fibrose.
Le développement cible la Maladie du Foie Gras Non Alcoolique (NAFLD), qui touche 30-40 % des adultes aux États-Unis, sa forme sévère NASH impactant 3-5 % de la population adulte. L'entreprise prévoit de lancer le produit Olive Cell en tant que nutraceutique en 2026, tout en explorant des partenariats pharmaceutiques.
Les tests, réalisés sur des cellules hépatiques humaines, ont montré la capacité du composé à réduire les niveaux de collagène de type 1 dans les cellules XL-2. Ce produit rejoindra VINIA® dans le portefeuille de BioHarvest, qui a déjà atteint plus de 50 millions de dollars de ventes avec plus de 50 000 abonnés actifs.
BioHarvest Sciences (NASDAQ: BHST) hat vielversprechende in vitro-Testresultate für ihre proprietäre Olive Cell-Verbindung bekannt gegeben, die eine reduzierte Fettansammlung in menschlichen Leberzellen zeigt. Die Verbindung, reich an Verbascosid, hat sich als wirksam erwiesen, um die Fettansammlung in Modellen der Lebersteatose und Fibrose zu mildern.
Die Entwicklung zielt auf Nicht-alkoholische Fettlebererkrankung (NAFLD), die 30-40% der Erwachsenen in den USA betrifft, wobei die schwere Form NASH 3-5% der erwachsenen Bevölkerung beeinflusst. Das Unternehmen plant, das Olive Cell-Produkt 2026 als Nutraceutical auf den Markt zu bringen, während es pharmazeutische Partnerschaften erkundet.
Die Tests, die an menschlichen Leberzellen durchgeführt wurden, zeigten die Fähigkeit der Verbindung, die Kollagen Typ 1-Spiegel in XL-2-Zellen zu reduzieren. Dieses Produkt wird zusammen mit VINIA® im Portfolio von BioHarvest sein, das bereits über 50 Millionen USD Umsatz mit mehr als 50.000 aktiven Abonnenten erzielt hat.
- In vitro tests demonstrate efficacy in reducing liver fat accumulation
- Large target market: 30-40% of US adults affected by NAFLD
- Product launch planned for 2026
- Potential pharmaceutical partnership opportunities
- Synergistic with existing successful VINIA® product ($50M+ sales)
- Product still in early testing phase
- No FDA approval as treatment yet
- Faces competition from existing treatments
- Additional studies required before commercialization
Insights
BioHarvest's in vitro results for their Olive Cell compound represent an early but potentially significant step in addressing the Non-Alcoholic Fatty Liver Disease (NAFLD) market that affects
The company's attribution of efficacy to Verbascoside, a polyphenol with established anti-inflammatory properties, provides a plausible mechanism of action. However, these are still preliminary laboratory findings that require validation through animal studies and eventually human clinical trials to establish therapeutic relevance.
BioHarvest's dual-path strategy is noteworthy - planning to launch as a nutraceutical in 2026 while exploring pharmaceutical partnerships. This approach could accelerate time-to-market and revenue generation while keeping options open for higher-value pharmaceutical applications. Their Botanical Synthesis platform's ability to produce high concentrations of plant compounds at industrial scale without GMO manipulation represents a significant manufacturing advantage if efficacy is proven.
The NAFLD market lacks FDA-approved treatments despite affecting over 100 million Americans, creating an opportunity for novel interventions. However, investors should recognize that nutraceutical products face lower regulatory barriers but typically command less pricing power than pharmaceuticals, potentially limiting revenue potential compared to prescription alternatives.
This announcement reflects BioHarvest's expansion of its product pipeline beyond VINIA, its flagship product that has achieved
The projected 2026 commercialization timeline gives investors a clear horizon for potential revenue contribution, though much work remains to validate these preliminary findings. The nutraceutical approach allows faster market entry but typically yields lower margins than pharmaceuticals. However, the company's mention of potential pharmaceutical partnerships through its CDMO model hints at multiple monetization strategies.
With a current market cap of
Cross-selling opportunities with the existing VINIA subscriber base could accelerate initial adoption if the product reaches market, potentially reducing customer acquisition costs. The company's ability to produce high concentrations of Verbascoside could also create differentiation in the crowded supplement market. However, conversion of these laboratory findings into a commercially successful product remains speculative at this early stage.
Non-Alcoholic Fatty Liver Disease (NAFLD) Affects 30
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced new 'in vitro' test results for the Company's proprietary new Olive Cell compound, which showed reduced fat accumulation in human liver cells. Fat accumulation in the liver is a leading cause of non-alcohol fatty liver disease (NAFLD), which affects 30
The Company attributes the positive test results of reducing fat accumulation in liver cells to the high levels of Verbascoside (a plant-derived polyphenol with known anti-inflammatory properties that has been researched for a variety of effects on the liver) in BioHarvest's Olive Cell compound. Hepatic fat accumulation can progress from simple NAFLD to non-alcoholic steatohepatitis (NASH) which includes hepatocellular injury, inflammation, and fibrosis. In more severe cases, complications such as liver cirrhosis and hepatocellular carcinoma may arise. NASH, the more severe form of NAFLD, affects 3
There are currently limited FDA-approved drugs specifically for NAFLD. Based on these results and additional studies to be conducted in 2025, the Company expects to begin selling the Olive Cell product in 2026 as a nutraceutical product, while continuing to explore the potential of partnering with a pharmaceutical company to provide the olive cell composition via a different regulatory path as part of its CDMO model.
The Company anticipates that this Olive Cell product will contain the highest levels of Verbascoside produced from olives in the global market. This unique compound was analyzed by Professor Maurizio Servili from University of Perugia, Italy, a leading worldwide expert of olive polyphenols.
BioHarvest's Botanical Synthesis platform elicits and magnifies plant-produced molecules like Verbascoside and produces them in non-GMO plant cells at industrial scale. The Olive product will join VINIA® as part of the Company's portfolio. VINIA®, a grape cell product that is high in Piceid Resveratrol, has been clinically shown to significantly dilate arteries, resulting in increased blood flow. The Company recently announced that VINIA® had surpassed
"Non-alcoholic fatty liver disease impacts over 100 million Americans, and as part of our mission to develop life-changing compounds from plants, we believe our Olive Cell Product will have the capacity to be a next-generation therapeutic solution for improving liver health in millions of American consumers," said Ilan Sobel, CEO of BioHarvest. "This product will be accretive to our nutraceuticals portfolio and will allow us to realize significant marketing and sales synergies with VINIA®, which has already over 50,000 active subscribers today."
"in vitro" Testing Details
In these BioHarvest tests, 'in vitro' models on human hepatic cells demonstrated that the Olive Cell compound mitigated fat accumulation in a liver steatosis model as well as in experimental models of liver fibrosis. The tests were conducted using an in-vitro model of Oleic acid (OA)-induced lipid accumulation in HepG2 cells, which is commonly used as a model for studying NAFLD. In addition to mitigating lipid accumulation in the liver steatosis model, the Olive Cell compound also succeeded in reducing the level of collagen type 1 in XL-2 cells in an in-vitro fibrosis model.
About VINIA®
VINIA® is the first commercial nutraceutical product derived from the Botanical Synthesis platform and is clinically proven to improve blood flow, which enhances physical energy and mental alertness. VINIA® contains multiple polyphenols, including Piceid Resveratrol, which is 25x more soluble in water than regular resveratrol. VINIA® significantly dilates arteries by increasing Nitric Oxide levels in the blood (which act as a vasodilator) and by reducing the Endothelin-1 levels in the blood (which act as a vasoconstrictor). VINIA® currently has over 8,000 verified online reviews and an average 4.8/5** consumer rating. To learn more, please visit www.vinia.com.
*https://liverfoundation.org/wp-content/uploads/2022/06/ALF-NAFLD-NASH-Infographic.pdf
**BioHarvest encourages all customers to leave honest and uncensored feedback. Customers receive a 30-day supply when they submit a review, whether positive or negative.
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
This press release may contain "forward-looking statements". "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." In particular , without limiting the generality of the foregoing, there is no assurance that the company will be able to partner with a pharmaceutical company to develop an FDA approved drug , such event is subject to uncertainties such as limited budgets for this type of drug development, acceptance by pharmaceutical company scientists of the potential for the compound as a drug and the potential market for the drug as well as the usual uncertainties related to clinical trials. In addition there is no assurance that the successful marketing program for Vinia will achieve the same or similar results for the olive cell product as such result depends on consumer preferences, consumer acceptance of potential health benefits, pricing and other similar factors.
You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and any other risks identified in other filings made by the Company with the Securities and Exchange Commission".
This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents.
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
+1 (604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
BHSC@mzgroup.us
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/243240
FAQ
What were the key findings of BioHarvest's (BHST) Olive Cell compound testing?
When will BioHarvest (BHST) launch its Olive Cell product?
What is the market potential for BHST's Olive Cell product in the US?
How does BHST's Olive Cell compound work against liver disease?
What are BHST's current product performance metrics?
